Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
6
|
pubmed:dateCreated |
1998-5-5
|
pubmed:abstractText |
Therapeutic effect of botulinum toxin A was studied in a group of pediatric patients (n = 28) aged between 6 months and 18 years. The patients were diagnosed with cervical dystonia (n = 6), adductor spasm of the hip (n = 8), spastic drop foot (n = 7) and various other focal motor problems associated with spastic muscular hyperactivity (n = 7). The mean dose of botulinum toxin A (Dysport) used to inject into the affected muscle was 22 U/kg body weight. Reduced muscular hyperactivity with a significant increase in joint mobility was achieved for dystonic (p < 0.0001) as well as for spastic conditions in patients with adductor spasm (p < 0.0002). For these patients the improved joint mobility represented a significant benefit for both daily activities and nursing care. Local paresis and local hematoma were observed in 1/28 and 1/28 patients, respectively; 1/28 patients developed a secondary non-response. However, apart from these side effects, no other adverse reactions to botulinum toxin A treatment were recorded during the treatment and observation period (12-64 months). Our results suggest that botulinum toxin A represents an effective and safe therapeutic substance for the treatment of pediatric patients suffering of focal motor problems due to dystonic or spastic muscular hyperactivity.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
Dec
|
pubmed:issn |
0174-304X
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
28
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
307-13
|
pubmed:dateRevised |
2010-11-18
|
pubmed:meshHeading |
pubmed-meshheading:9453027-Adolescent,
pubmed-meshheading:9453027-Botulinum Toxins, Type A,
pubmed-meshheading:9453027-Child,
pubmed-meshheading:9453027-Child, Preschool,
pubmed-meshheading:9453027-Dose-Response Relationship, Drug,
pubmed-meshheading:9453027-Dystonia,
pubmed-meshheading:9453027-Electromyography,
pubmed-meshheading:9453027-Female,
pubmed-meshheading:9453027-Humans,
pubmed-meshheading:9453027-Infant,
pubmed-meshheading:9453027-Male,
pubmed-meshheading:9453027-Muscle, Skeletal,
pubmed-meshheading:9453027-Muscle Spasticity,
pubmed-meshheading:9453027-Neurology,
pubmed-meshheading:9453027-Neuromuscular Agents,
pubmed-meshheading:9453027-Pediatrics,
pubmed-meshheading:9453027-Severity of Illness Index
|
pubmed:year |
1997
|
pubmed:articleTitle |
Interventional neuropediatrics: treatment of dystonic and spastic muscular hyperactivity with botulinum toxin A.
|
pubmed:affiliation |
Department of Neuropediatrics, University Hospital Freiburg, Germany.
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Comparative Study
|